Financhill
Sell
47

MSCI Quote, Financials, Valuation and Earnings

Last price:
$581.14
Seasonality move :
7.24%
Day range:
$578.15 - $593.64
52-week range:
$486.74 - $634.99
Dividend yield:
1.24%
P/E ratio:
36.68x
P/S ratio:
14.69x
P/B ratio:
--
Volume:
425.4K
Avg. volume:
630.3K
1-year change:
-2.14%
Market cap:
$43.5B
Revenue:
$2.9B
EPS (TTM):
$15.78

Analysts' Opinion

  • Consensus Rating
    MSCI, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 1 Hold rating, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $656.73, MSCI, Inc. has an estimated upside of 13.49% from its current price of $578.69.
  • Price Target Downside
    According to analysts, the lowest downside price target is $535.00 representing 100% downside risk from its current price of $578.69.

Fair Value

  • According to the consensus of 9 analysts, MSCI, Inc. has 13.49% upside to fair value with a price target of $656.73 per share.

MSCI vs. S&P 500

  • Over the past 5 trading days, MSCI, Inc. has underperformed the S&P 500 by -1.51% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • MSCI, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • MSCI, Inc. has grown year-over-year revenues for 43 quarters straight. In the most recent quarter MSCI, Inc. reported revenues of $793.4M.

Earnings Growth

  • MSCI, Inc. has grown year-over-year earnings for 3 quarters straight. In the most recent quarter MSCI, Inc. reported earnings per share of $4.25.
Enterprise value:
48.7B
EV / Invested capital:
--
Price / LTM sales:
14.69x
EV / EBIT:
29.44x
EV / Revenue:
15.95x
PEG ratio (5yr expected):
10.20x
EV / Free cash flow:
35.10x
Price / Operating cash flow:
32.33x
Enterprise value / EBITDA:
26.05x
Gross Profit (TTM):
$2.3B
Return On Assets:
22.68%
Net Income Margin (TTM):
40.03%
Return On Equity:
--
Return On Invested Capital:
32.47%
Operating Margin:
56.43%
Trailing 12 Months Fiscal Quarters
Period Ending 2023-09-30 2024-09-30 2025-09-30 2024-09-30 2025-09-30
Income Statement
Revenue $2.4B $2.8B $3.1B $724.7M $793.4M
Gross Profit $1.9B $2.1B $2.3B $552.2M $614.2M
Operating Income $1.3B $1.5B $1.7B $404.4M $447.7M
EBITDA $1.5B $1.7B $1.9B $458.4M $500.8M
Diluted EPS $11.99 $15.23 $15.78 $3.57 $4.25
Period Ending 2021-09-30 2022-09-30 2023-09-30 2024-09-30 2025-09-30
Balance Sheet
Current Assets $1.8B $1.5B $1.6B $1.3B $1.3B
Total Assets $5.1B $4.8B $4.9B $5.4B $5.4B
Current Liabilities $1B $1.1B $1.2B $1.4B $1.5B
Total Liabilities $5.4B $5.9B $5.9B $6.2B $7.3B
Total Equity -$280M -$1.1B -$1B -$751M -$1.9B
Total Debt $4.3B $4.7B $4.6B $4.6B $5.6B
Trailing 12 Months Fiscal Quarters
Period Ending 2023-09-30 2024-09-30 2025-09-30 2024-09-30 2025-09-30
Cash Flow Statement
Cash Flow Operations $1.2B $1.5B $1.5B $421.6M $449.4M
Cash From Investing -$96.3M -$857.5M -$130.3M -$28.1M -$26.1M
Cash From Financing -$1B -$1B -$1.5B -$350.3M -$369.4M
Free Cash Flow $1.1B $1.4B $1.4B $394M $423.3M
MSCI
Sector
Market Cap
$43.5B
$533.3M
Price % of 52-Week High
91.13%
91.08%
Dividend Yield
1.24%
1.54%
Shareholder Yield
5.33%
3.06%
1-Year Price Total Return
-2.14%
7.8%
Beta (5-Year)
1.305
0.456
Dividend yield:
1.24%
Annualized payout:
$6.40
Payout ratio:
42.36%
Growth streak:
0 years

Technicals

8-day SMA
Sell
Level $579.40
200-day SMA
Buy
Level $560.50
Bollinger Bands (100)
Buy
Level 549.2 - 577.88
Chaikin Money Flow
Buy
Level 121.3M
20-day SMA
Buy
Level $567.37
Relative Strength Index (RSI14)
Buy
Level 56.54
ADX Line
Buy
Level 17.46
Williams %R
Neutral
Level -34.6787
50-day SMA
Buy
Level $566.20
MACD (12, 26)
Buy
Level 6.15
25-day Aroon Oscillator
Buy
Level 72
On Balance Volume
Neutral
Level 83.9M

Financial Scores

Buy
Altman Z-Score (Annual)
Level (7.0137)
Sell
CA Score (Annual)
Level (-1.9973)
Buy
Beneish M-Score (Annual)
Level (-2.8224)
Sell
Momentum Score
Level (4)
Sell
Ohlson Score
Level (3.2731)
Buy
Piotroski F Score (Annual)
Level (6)
Buy
Quality Ratio Score
Level (8)
Sell
Fundamental Score
Level (6)

Revenue Forecast

Earnings per Share Forecast

Company Profile

MSCI, Inc. engages in the provision of investment decision support tools including indices, portfolio risk and performance analytics and corporate governance products and services. It operates through the following segments: Index, Analytics, ESG and Climate, and All Other-Private Assets. The Index segment focuses on the investment process, including developing indexed financial products. The Analytics segment offers risk management, performance attribution and portfolio management content, applications, and services. The ESG and Climate segment includes providing data, ratings, research, and tools to help investors navigate increasing regulation, meet new client demands and better integrate ESG and climate elements into their investment processes. The All Other-Private Assets segment refers to the business intelligence products to real estate owners, managers, developers, and brokers. The company was founded by Andrew Thomas Rudd in 1998 and is headquartered in New York, NY.

Stock Forecast FAQ

In the current month, MSCI has received 8 Buy ratings 1 Hold ratings, and 0 Sell ratings. The MSCI average analyst price target in the past 3 months is $656.73.

  • Where Will MSCI, Inc. Stock Be In 1 Year?

    According to analysts, the consensus estimate is that MSCI, Inc. share price will rise to $656.73 per share over the next 12 months.

  • What Do Analysts Say About MSCI, Inc.?

    Analysts are divided on their view about MSCI, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that MSCI, Inc. is a Sell and believe this share price will drop from its current level to $535.00.

  • What Is MSCI, Inc.'s Price Target?

    The price target for MSCI, Inc. over the next 1-year time period is forecast to be $656.73 according to 9 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.

  • Is MSCI A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for MSCI, Inc. is a Buy. 8 of 9 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of MSCI?

    You can purchase shares of MSCI, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase MSCI, Inc. shares.

  • What Is The MSCI, Inc. Share Price Today?

    MSCI, Inc. was last trading at $581.14 per share. This represents the most recent stock quote for MSCI, Inc.. Yesterday, MSCI, Inc. closed at $578.69 per share.

  • How To Buy MSCI, Inc. Stock Online?

    In order to purchase MSCI, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Did Stan Druckenmiller Sell Broadcom Stock?
Why Did Stan Druckenmiller Sell Broadcom Stock?

In Q3, legendary macro investor Stan Druckenmiller sold his entire…

Why Is CoreWeave Stock Down So Much?
Why Is CoreWeave Stock Down So Much?

AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…

Why Did Stan Druckenmiller Buy MercadoLibre Stock?
Why Did Stan Druckenmiller Buy MercadoLibre Stock?

In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…

Stock Ideas

Buy
59
Is NVDA Stock a Buy?

Market Cap: $4.6T
P/E Ratio: 64x

Buy
65
Is GOOG Stock a Buy?

Market Cap: $3.9T
P/E Ratio: 40x

Buy
51
Is GOOGL Stock a Buy?

Market Cap: $3.9T
P/E Ratio: 40x

Alerts

Buy
70
RGC alert for Jan 8

Regencell Bioscience Holdings Ltd. [RGC] is down 21.5% over the past day.

Buy
64
RVMD alert for Jan 8

Revolution Medicines, Inc. [RVMD] is up 4.61% over the past day.

Sell
38
CRNX alert for Jan 8

Crinetics Pharmaceuticals, Inc. [CRNX] is down 0.23% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock